Dr. Dong interviewed for Science in the City Publication of the Week

Date Posted: 
2019-04-10
Dr. Xuesen Dong

A recent publication from Dr Xuesen Dong and team is featured as Science in the City's Publication of the Week. "RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression" was published in European Urology.

The results in this publication provide insights on designing future therapeutic strategies to control neuroendocrine prostate cancer (NEPC)  development and progression. Specifically, this study defines the molecular mechanism by which the RNA splicing factor SRRM4 modulates RNA splicing of the histone demethylase BHC80 to confer cancer cells growth advantages and promote NEPC progression. It links RNA splicing and epigenetic modification of histones that can trigger the immune responses of tumour cells to induce multiple tumour promoting cytokines. Having shown that the major downstream effector of SRRM4-BH80 axis involves MyD88 signalling, the publication provides proof-of-principle evidence that MyD88 inhibitors can suppress the growth of NEPC spheroids and xenografts.

This research was supported by the CIHR, Prostate Cancer Canada, the Terry Fox Research Institute and NIH Prostate Cancer SPORE.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Fathers Day Walk Run 2019

Raymond James Father's Day Walk Run Fundraiser, June 16, 2019

The 21st Annual Raymond James Walk Run fundraiser for Prostate Cancer Foundation BC took place on Sunday June 16, 2019 in various locations across BC. The sponsorship page is still accepting donations;  click here to sponsor our Centre's team (opens in new window).

 

Employment

Work at the Vancouver Prostate Centre

Monday, July 8, 2019

Dr. Flannigan to lead clinical trial for scrotal pain treatment

Dr. Flannigan
Monday, June 3, 2019

Benefits Seen With Apalutamide Plus ADT in Metastatic Castration-Sensitive Prostate Cancer

Dr. Chi